Announcement on Convening Performance Briefing for 2025 and Q1 2026
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
Link of Full Text for Reference:
Announcement on Convening Performance Briefing for 2025 and Q1 2026
Filed with SSE · · 2 pages · Chinese
Release
Mayinglong Pharmaceutical Group Co., Ltd. on 6ix
Earlier from Mayinglong Pharmaceutical
- Notice on Convening the 2025 Annual General Meeting
- Announcement on Obtaining Drug Registration Certificate by Subsidiary
- Announcement on Termination of the Transfer of Equity of Subsidiary Holding Company by the Holding Subsidiary
- 2025 Annual Report
- Announcement on Transfer of Equity of Subsidiary Holding Company by the Holding Subsidiary
Later from Mayinglong Pharmaceutical
- Announcement on Resolutions of the 2025 Annual General Meeting
- Announcement on Obtaining Drug Registration Certificate
- Announcement on Attending the 2026 Collective Reception Day for Investors of Listed Companies in Hubei Jurisdiction
- Announcement on the Inclusion of the Company's Pharmaceutical Products in the "National Essential Medicines List"
- Announcement on the Listing and Trading of Restricted Shares from the Share Reform
Follow Mayinglong Pharmaceutical into a list and get an email when it puts out news.
Follow Mayinglong Pharmaceutical